Paper41594658
Resveratrol for Cancer Treatment: Effects on Metabolism and Immune Cells.
Bao R and 2 others. Biomolecules, 2026. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Resveratrol for Cancer Treatment: Effects on Metabolism and Immune Cells. Papers, record 41594658. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41594658
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Resveratrol | Major topic |
| Neoplasms | Major topic |
| Antineoplastic Agents, Phytogenic | Major topic |
| Humans | |
| Animals | |
| Tumor Microenvironment | |
| Metabolic Reprogramming | |
| Glycolysis | |
| Macrophages |
Source PubMed
References163
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38649722 | Cancer cell metabolism and antitumour immunity. | Nat Rev Immunol | 2024 | https://conductscience.org/library/papers/38649722 | PubMed |
| 2 | 34027036 | The PIDDosome: centrosome guardian and backup on the DNA damage response. | Mol Cell Oncol | 2021 | https://conductscience.org/library/papers/34027036 | PubMed |
| 3 | 32849616 | Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. | Front Immunol | 2020 | https://conductscience.org/library/papers/32849616 | PubMed |
| 4 | 39761424 | Resveratrol amplifies the anti-tumor effect of α-PD-1 by altering the intestinal microbiome and PGD2 content. | Gut Microbes | 2025 | https://conductscience.org/library/papers/39761424 | PubMed |
| 5 | 34859370 | Resveratrol enhanced chemosensitivity by reversing macrophage polarization in breast cancer. | Clin Transl Oncol | 2022 | https://conductscience.org/library/papers/34859370 | PubMed |
| 6 | 40917691 | Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior in vivo T cell history. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/40917691 | PubMed |
| 7 | 26321679 | Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. | Cell | 2015 | https://conductscience.org/library/papers/26321679 | PubMed |
| 8 | 37836529 | Cancer Metabolism as a Therapeutic Target and Review of Interventions. | Nutrients | 2023 | https://conductscience.org/library/papers/37836529 | PubMed |
| 9 | 36430164 | Mechanism of Resveratrol-Induced Programmed Cell Death and New Drug Discovery against Cancer: A Review. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430164 | PubMed |
| 10 | 36091247 | Regulation of dietary polyphenols on cancer cell pyroptosis and the tumor immune microenvironment. | Front Nutr | 2022 | https://conductscience.org/library/papers/36091247 | PubMed |
| 11 | 32937636 | In vivo Anti-Cancer Effects of Resveratrol Mediated by NK Cell Activation. | J Innate Immun | 2021 | https://conductscience.org/library/papers/32937636 | PubMed |
| 12 | 35056739 | Resveratrol and Immune Cells: A Link to Improve Human Health. | Molecules | 2022 | https://conductscience.org/library/papers/35056739 | PubMed |
| 13 | 34052324 | Resveratrol for cancer therapy: Challenges and future perspectives. | Cancer Lett | 2021 | https://conductscience.org/library/papers/34052324 | PubMed |
| 14 | 38685033 | CD8+ T cell-based cancer immunotherapy. | J Transl Med | 2024 | https://conductscience.org/library/papers/38685033 | PubMed |
| 15 | 40141030 | Bid Protein: A Participant in the Apoptotic Network with Roles in Viral Infections. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40141030 | PubMed |
| 16 | 31478911 | Killers 2.0: NK cell therapies at the forefront of cancer control. | J Clin Invest | 2019 | https://conductscience.org/library/papers/31478911 | PubMed |
| 17 | 36768924 | Modulating Glycolysis to Improve Cancer Therapy. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768924 | PubMed |
| 18 | 32934330 | Exploring the NK cell platform for cancer immunotherapy. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/32934330 | PubMed |
| 19 | 30808985 | Immunometabolism and natural killer cell responses. | Nat Rev Immunol | 2019 | https://conductscience.org/library/papers/30808985 | PubMed |
| 20 | 36800999 | Spatial profiling technologies illuminate the tumor microenvironment. | Cancer Cell | 2023 | https://conductscience.org/library/papers/36800999 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42877341 | Resveratrol-Loaded Responsive Core-Shell Tecto Dendrimers Potentiate Hepatocellular Carcinoma Therapy. | Biomater Res | 2026 | https://conductscience.org/library/papers/42877341 | PubMed |
| 42654091 | Development and Characterization of Polylactic Acid-Resveratrol-Based Polymeric Nanoparticles and Their Cytotoxic Effect on Two Breast Cancer Cell Lines in Combination with Doxorubicin. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42654091 | PubMed |
| 42358819 | Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities. | Oncol Res | 2026 | https://conductscience.org/library/papers/42358819 | PubMed |
| 42196257 | Plant-Derived Bioactive Compounds and Their Therapeutic Potential in Cancer. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196257 | PubMed |
| 41977169 | Resveratrol as a Modulator of Adriamycin-, Taxol-, and Cisplatin-Induced Cytotoxicity in MCF-7 Breast Cancer Cells. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977169 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41594658
GET https://conductscience.org/api/papers/v1/41594658/references?page=2